Limited Offer
Advanced Vaccination Technologies for Infectious and Chronic Diseases
A guide to Vaccinology
- 1st Edition - March 25, 2024
- Editors: Vasso Apostolopoulos, Lalitkumar K. Vora, Vivek P. Chavda
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 5 6 4 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 5 6 5 - 6
Advanced Vaccination Technologies for Infectious and Chronic Diseases is a comprehensive guide that delves into the intricate details of vaccine design, development across vario… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvanced Vaccination Technologies for Infectious and Chronic Diseases is a comprehensive guide that delves into the intricate details of vaccine design, development across various platforms, and the path to commercialization. This book provides an introductory overview of vaccines, covering various types, developmental methodologies, delivery systems, adjuvants, immunization, and measurement of vaccine efficacy. It also showcases examples of vaccine research efforts targeting infectious diseases, autoimmune disorders, and cancer. The book concludes by exploring cutting-edge advances in proteogenomics, immunopeptidomics, and future vaccine technologies.
The primary objective of this book is to inform a broad scientific audience about the fundamental concepts underlying vaccine and immunology. Further, it serves as an invaluable reference for understanding the critical steps in the journey from discovery to regulatory processes for human clinical trials, addressing common misconceptions and presenting factual information about vaccinations. Advanced Vaccination Technologies for Infectious and Chronic Diseases is a requisite reference for occupational health professionals whose roles involve supervision of immunization programs such as those working within the National Health Service, some sectors of higher education, or the pharmaceutical industry. It also caters to those researchers engaged in vaccine development and all who want to learn the processes involved from laboratory research to final product.
- Offers comprehensive coverage of different vaccine platforms and their development
- Includes information on the regulatory perspective of vaccine development
- Describes different delivery approaches for vaccinology
- Explains the clinical development of vaccines along with novel platforms
- Covers all recent developments of vaccine production technologies, new types of vaccines, and ongoing research that could prevent future pandemics
Graduates, post-graduates, researchers, scientists in the field of immunology, drug delivery, biology, engineering, medicine, pharmacuticals technology, medical professionals and other interdisciplinary fields of science and technology involved in developing vaccines
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Biography
- Foreword
- Preface
- Chapter 1. History of vaccination
- 1. Introduction
- 2. History of vaccines
- 3. Basic formulation of vaccines
- 4. Types of vaccines
- 5. Different routes of vaccine administration and their immune reactions
- 6. Vaccine hesitancy
- 7. Manufacturing procedure
- 8. Regulation, clinical, and ethics approval
- 9. Conclusion and future prospects
- Chapter 2. Vaccine adjuvants and carriers
- 1. Vaccine adjuvants
- 2. Carriers
- Chapter 3. Conventional vaccination methods: Inactivated and live attenuated vaccines
- 1. Background
- 2. Live attenuated vaccines
- 3. Inactivated vaccines
- 4. Conclusion and future directions
- Chapter 4. Subunit protein-based vaccines
- 1. Introduction
- 2. Subunit-based vaccines, overview
- 3. Subunit vaccines: Preclinical studies
- 4. Subunit vaccines: Human clinical trials
- 5. Subunit vaccines: Approved for human use
- 6. Mechanism of action of subunit protein-based vaccines
- 7. Conclusion
- Chapter 5. Peptide-based vaccines and altered peptide ligands: Multiple sclerosis paving the way
- 1. Introduction
- 2. Linear altered peptide ligands
- 3. Aza-altered peptide ligand analogs
- 4. Cyclic altered peptide ligands
- 5. Citrullinated altered peptide ligands
- 6. Neuropathic pain
- 7. Thiopalmitoylation of altered peptide ligands
- 8. Myelin peptides—Mannan conjugates with or without altered peptide ligands
- 9. Molecular modeling of altered peptide ligands
- 10. Conclusions
- Chapter 6. Vector-based vaccine delivery and associated immunity: Current status and way forward
- 1. Introduction
- 2. Type of vectors harnessing
- 3. Nanomaterial delivery systems
- 4. Type(s) and magnitude of the induced immune responses
- 5. Vaccines on market
- 6. A look into the future
- Chapter 7. It is all in the delivery: How to augment the efficiency of DNA vaccination
- 1. Preamble
- 2. History
- 3. Advantages of DNA vaccines
- 4. Mechanism of action
- 5. Current state of DNA vaccines
- 6. Vaccine vector design
- 7. Route of delivery
- 8. Improving the immunogenicity of DNA vaccines
- 9. Nanoparticle delivery systems
- 10. Nanoparticle materials
- 11. Lipids as vaccine adjuvants
- 12. MPLA adjuvant
- 13. Concluding remarks
- Chapter 8. Plant-based vaccines for emerging infectious diseases
- 1. Introduction
- 2. Plant biotechnological-derived virus-like particles as a vaccine
- 3. Biotechnological methods for transient expression of the desired protein in plants
- 4. Plant-based VLP vaccines for COVID-19 and influenza
- 5. Safety considerations for plant-based vaccines
- 6. Regulatory and legal perspectives on plant-based vaccines
- 7. Conclusion
- 8. Expert opinion
- Chapter 9. Expression system and purification process for the vaccine production
- 1. Introduction
- 2. Expression systems for vaccine production
- 3. Upstream processing
- 4. Downstream processing/purification of the vaccines
- 5. Analytical methods
- 6. Conclusion and future prospects
- Chapter 10. Targeting dendritic cells for antigen delivery in vaccine design
- 1. Introduction
- 2. Mannose receptor
- 3. DEC-205
- 4. DC-SIGN
- 5. L-SIGN
- 6. Langerin
- 7. MGL
- 8. Dectin-1
- 9. Conclusion
- Chapter 11. Parenteral vaccine delivery: From basic principles to new developments
- 1. Introduction
- 2. History
- 3. Vaccination programs having a significant impact on global health
- 4. Types of parenteral vaccines
- 5. Injection techniques for vaccine administration
- 6. Production, storage, and distribution of vaccines
- 7. Guidelines and regulations for vaccine development
- 8. Future development
- 9. Conclusion
- Chapter 12. Mucosal vaccine delivery
- 1. Introduction
- 2. Mucosal immunity
- 3. Induction of mucosal immune responses
- 4. Advantages of mucosal vaccines
- 5. Mucosal vaccine formulations
- 6. Mucosal vaccine approaches
- 7. Mucosal vaccines under development
- 8. Challenges
- 9. Conclusion
- Chapter 13. Personalized vaccines, novel vaccination technologies, and future prospects
- 1. Introduction
- 2. Understanding pathology-specific vaccination
- 3. Tailoring vaccines to individual needs
- 4. Future vaccine technologies
- 5. Assessing vaccine efficacy
- 6. Challenges and opportunities in personalized and future vaccines
- 7. Conclusion
- Chapter 14. The application of nanoparticle-based delivery systems in vaccine development
- 1. Introduction
- 2. Types of nanocarriers in vaccine development
- 3. Lipid NPs
- 4. Polymer NPs
- 5. Immunostimulating complexes
- 6. Emulsions
- 7. The delivery of nanovaccines
- 8. NPs-based vaccines in clinical trials
- 9. Discussion and future directions
- 10. Conclusion
- Chapter 15. Preclinical and clinical development for vaccines and formulations
- 1. Introduction
- 2. History of vaccine development
- 3. Types of vaccines
- 4. Preclinical development of vaccines
- 5. Clinical development of vaccines
- 6. Conclusion
- Chapter 16. Regulatory processes involved in clinical trials and intellectual property rights around vaccine development
- 1. Introduction
- 2. Clinical trials for vaccines
- 3. Regulatory authorities regarding vaccine products
- 4. Global regulatory frameworks
- 5. Clinical trial management
- 6. Conclusion
- Chapter 17. Vaccine safety, efficacy, and ethical considerations
- 1. Introduction
- 2. Vaccine safety
- 3. Vaccine efficacy
- 4. Conclusion and future prospects
- Chapter 18. Regulatory consideration and pathways for vaccine development
- 1. Introduction
- 2. Vaccine development stages with their regulatory considerations
- 3. Vaccine manufacturing considerations (QC-related aspects)
- 4. Vaccine regulatory approval pathways
- 5. Challenges in vaccine development: Why and what to do?
- 6. Conclusions
- Chapter 19. New approaches to vaccines for infectious diseases
- 1. Introduction
- 2. Novel vaccine antigens
- 3. Novel vaccine antigen carrier systems
- 4. Novel vaccination routes
- 5. Conclusion
- Chapter 20. New approaches to vaccines for cancer
- 1. Introduction
- 2. History of cancer vaccines
- 3. Cancer vaccines based on their application
- 4. Target antigens for cancer vaccines
- 5. Vaccine development techniques
- 6. Adjuvants
- 7. Vaccine resistance
- 8. Combination therapy
- 9. Conclusion
- Chapter 21. New approaches to vaccines for autoimmunity
- 1. Introduction
- 2. Infection-induced autoimmunity
- 3. Adjuvant-induced autoimmunity
- 4. Vaccination and autoimmune disease
- 5. New-generation vaccines
- 6. Concluding remarks
- Chapter 22. The fast-track development of COVID-19 vaccines
- 1. Introduction
- 2. COVID-19 vaccines that were accepted for the emergency use authorization and others under phase 3 clinical trials
- 3. Immune responses against SARS-CoV-2 vaccines' durability
- 4. Homologous versus heterologous COVID-19 prime-boost immunization strategies: To mix or not to mix?
- 5. The rapid development of COVID vaccines compared to traditional vaccines
- 6. Waning of COVID-19 vaccines immunity
- 7. Post COVID-19 vaccinations sequelae
- 8. Challenges and ethics related to the COVID-19 vaccine research
- 9. Conclusions and recommendations
- Chapter 23. Myths and facts about vaccination: Dispelling myths and misconceptions with science
- 1. Introduction
- 2. Antivaccine movement and its impact in society
- 3. Myths and misinformation
- 4. Spread and susceptibility
- 5. Facts and measures to prevent the spread of misinformation
- 6. Justifying the common facts of vaccination
- 7. Handling of the misinformation
- 8. Myths and facts of COVID-19 vaccines
- 9. Conclusion
- Chapter 24. Proteogenomics and immunopeptidomics in the development of advanced vaccines
- 1. Introduction
- 2. Omics-based technology
- 3. Proteogenomics
- 4. Immune peptidomics
- 5. Challenges in proteogenomics and immunopeptidomics vaccine development
- 6. Future prospective
- 7. Conclusion
- Chapter 25. Nanoparticle-based vaccines and future vaccine technologies
- 1. Introduction
- 2. Types of nanoparticles for vaccine delivery
- 3. Mechanisms of vaccine delivery by nanoparticles
- 4. Challenges and limitations
- 5. Recent advances and future directions
- 6. Conclusion
- Index
- No. of pages: 528
- Language: English
- Edition: 1
- Published: March 25, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443185649
- eBook ISBN: 9780443185656
VA
Vasso Apostolopoulos
LV
Lalitkumar K. Vora
VC